Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

IV infiltration and extravasation remind this cancer patient of the constant challenges of speaking up and advocating for ...

An expert discusses the importance of timely biomarker testing and emerging challenges in treatment sequencing for metastatic ...

# AN emotional bell-ringing ceremony at the Cancer Centre Bahamas turned into a powerful moment of joy and healing for ...

Roche’s Itovebi gets European approval to treat people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation: Basel Thursday, July 24, 2025, 09:00 Hrs [ ...

Circus Extreme is back, featuring breathtaking stunts and aerialist Laura Miller - a breast cancer survivor who has reclaimed ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

After her battle with Stage 3 breast cancer, LaTonya Jordan of South Carolina rang the cancer free bell yesterday at the Cancer Centre Bahamas on New Providence.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

A new study published in Nanotechnology offers new hope for less harmful breast cancer therapy by combining two powerful, non ...